|
Janet Woodcock, MD
Principal Deputy Commissioner
US Food & Drug Administration
|
Janet Woodcock is the FDA’s Principal Deputy Commissioner. In this role, she works closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helps oversee the agency’s day-to-day functions. She served as the Acting Commissioner of Food and Drugs from Jan. 20, 2021, until Feb. 17, 2022.
Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research (CBER) where she served as the Director of the Division of Biological Investigational New Drugs and as Acting Deputy Director and Director of CBER’s Office of Therapeutics Research and Review, which oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis during her tenure.
In 1994, she was named Director of the FDA’s Center for Drug Evaluation and Research (CDER), leading the Center’s work that is the world’s gold standard for drug approval and safety.
In 2004, she became the FDA’s Deputy Commissioner and Chief Medical Officer. Later she took on other executive leadership positions in the Commissioner’s Office, including Deputy Commissioner for Operations and Chief Operating Officer.
In 2007, she returned as Director of CDER until asked to be the therapeutics lead for “Operation Warp Speed” in early 2020. This entailed supporting the development, evaluation, and availability of treatments such as monoclonal antibodies and antiviral drugs for patients with COVID-19.
Dr. Woodcock holds a Bachelor of Science in chemistry from Bucknell University (Lewisburg, PA), and a Doctor of Medicine from the Feinberg School of Medicine at Northwestern University Medical School (Chicago). She is board certified in internal medicine.
Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research (CBER) where she served as the Director of the Division of Biological Investigational New Drugs and as Acting Deputy Director and Director of CBER’s Office of Therapeutics Research and Review, which oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis during her tenure.
In 1994, she was named Director of the FDA’s Center for Drug Evaluation and Research (CDER), leading the Center’s work that is the world’s gold standard for drug approval and safety.
In 2004, she became the FDA’s Deputy Commissioner and Chief Medical Officer. Later she took on other executive leadership positions in the Commissioner’s Office, including Deputy Commissioner for Operations and Chief Operating Officer.
In 2007, she returned as Director of CDER until asked to be the therapeutics lead for “Operation Warp Speed” in early 2020. This entailed supporting the development, evaluation, and availability of treatments such as monoclonal antibodies and antiviral drugs for patients with COVID-19.
Dr. Woodcock holds a Bachelor of Science in chemistry from Bucknell University (Lewisburg, PA), and a Doctor of Medicine from the Feinberg School of Medicine at Northwestern University Medical School (Chicago). She is board certified in internal medicine.